• YAKHAK HOEJI
• /
• v.57 no.3
• /
• pp.213-218
• /
• 2013

This study examines factors associated with fixed budgets for pharmaceuticals and clawback system for pharmaceutical industry in European countries. We used information from a survey held in 2005~2006 by Austrian Health Institute. Several information including pharmaceutical pricing policies, marketing conditions for pharmaceutical industry and patient' choice of drugs was collected. Five out of twenty five countries in EU were considered as countries with fixed budgets for pharmaceuticals and remaining 20 countries were considered as countries without fixed budget system. Comparisons were made for each information. Countries with fixed budgets for pharmaceuticals were more likely to have internal (or external) reference pricing system and other pricing mechanisms. In addition, they were more likely to permit pharmaceutical industry to be engaged in public advertising and information provision towards patients. They guaranteed patient participation in drug choice decisions. The countries with fixed budgets for pharmaceuticals were more likely to have conditions that enable the fixed budget system to work better compared to those without fixed budget system. Therefore, the study results imply that we need to check whether we have similar conditions to the countries that already have fixed budgets for pharmaceuticals when we want to introduce fixed budget mechanism for pharmaceuticals in Korea in the future.

• Biomolecules & Therapeutics
• /
• v.12 no.2
• /
• pp.114-121
• /
• 2004

This study was undertaken to evaluate the general pharmacological properties of CJ-11828, an amlodipine adipate, in experimental animals and in vitro system. CJ-11828 had no effects on general behavior, motor coordination, writhing syndromes, pentetrazol-induced chemoshock and electric shock in mice at dose levels of 3,10, anti 30 mg/kg, po. But there were decrease of body temperature, prolongation of sleeping time, and inhibition of intestinal activity in mice treated with CJ-11828 at doses of 10 and 30 mg/kg, po. CJ-11828 decreased the blood pressure in coscuous fog at the dose level of 2mg/kg, po, but it was expected as a result of pharmacological activity of CJ-11828. Any effect on respiratory system was not observed in conscious rat at doses of 3,10, and 30 mg/kg, po. The slight decrease in spontaneous motor activity was observed in mice treated with CJ-11828 at high dose, 30 mg/kg. In vitro experiments, CJ-11828 had no effect on agonists-induced contraction of isolated guinea pig ileum at 0.1, 1, and 10 ${\mu}$M. Based on these results, it was concluded that CJ-11828 had no pharmacological effect ill these studies even up to the 36-fold anticipated clinical dose, 3 mg/kg.

• Proceedings of the PSK Conference
• /
• 2005.11a
• /
• pp.246-246
• /
• 2005

• Environmental Engineering Research
• /
• v.14 no.3
• /
• pp.186-194
• /
• 2009

Understanding the environmental fate of human and animal pharmaceuticals and their risk assessment are of great importance due to their growing environmental concerns. Although there are many potential pathways for them to reach the environment, effluents from sewage treatment plants (STPs) are recognized as major point sources. In this study, the removal efficiencies of the 43 selected priority pharmaceuticals in a conventional STP were evaluated using two simple models: an equilibrium partitioning model (EPM) and STPWIN$^{TM}$ program developed by US EPA. It was expected that many pharmaceuticals are not likely to be removed by conventional activated sludge processes because of their relatively low sorption potential to suspended sludge and low biodegradability. Only a few pharmaceuticals were predicted to be easily removed by sorption or biodegradation, and hence a conventional STP may not protect the environment from the release of unwanted pharmaceuticals. However, the prediction made in this study strongly relies on sorption coefficient to suspended sludge and biodegradation half-lives, which may vary significantly depending on models. Removal efficiencies predicted using the EPM were typically higher than those predicted by STPWIN for many hydrophilic pharmaceuticals due to the difference in prediction method for sorption coefficients. Comparison with experimental organic carbon-water partition coefficients ($K_{ocs}) revealed that log KOW-based estimation used in STPWIN is likely to underestimate sorption coefficients, thus resulting low removal efficiency by sorption. Predicted values by the EPM were consistent with limited experimental data although this model does not include biodegradation processes, implying that this simple model can be very useful with reliable Koc values. Because there are not many experimental data available for priority pharmaceuticals to evaluate the model performance, it should be important to obtain reliable experimental data including sorption coefficients and biodegradation rate constants for the prediction of the fate of the selected pharmaceuticals.

• Proceedings of the PSK Conference
• /
• 2002.10a
• /
• pp.355.3-356
• /
• 2002

Prostaglandins are synthesized by the enzyme cyclooxygenase (COX). Both constitutive (COX-1) and inducible (COX-2) isoforms have been identified. COX-2 expression is stimulated by inflammatory mediators such as growth factors and cytokines. Most non-steroidal anti-inflammatory drugs (NSAIDS) inhibit both isoforms of COX. Recent evidence suggests that selective inhibitors of COX-2 may possess diminished side effects reletive to common NSAIDS. Novel isothiazoles and isoxazoles were identified as selective inhibitiors of cycloxygenase-2(COX-2). (omitted)

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.7 no.2
• /
• pp.147-152
• /
• 2021

C-11 Radiolabeled amino acid-based radiopharmaceuticals such as [¹¹C]MET for brain tumor PET imaging have limitations due to their short half-life (20 min). F-18 radiolabeled amino acid derivatives have been developed to overcome for the short half-life, one of which is [¹⁸F]FET. Brain tumor imaging using [¹⁸F]FET showed high uptake in tumor region and no non-specific uptake in inflammatory tissue, which was useful in discriminating the difference between inflammation and tumor especially. In this study, [¹⁸F]FET was synthesized using an automatic synthesis module and quality tests were carried out including enantiomeric purity analysis with reference compounds. Radiochemical yield was 50.3 ± 4.9% (n=7, decay-corrected) with molar activity of 76 ± 17 GBq/mmol. The radiochemical purity of >99%. Enantiomeric purity of [¹⁸F]FET using chiral HPLC analysis showed >99%, which was confirmed by co-injection with the L-FET and D-FET authentic standards. [¹⁸F]FET was prepared with high radiochemical yield and molar activity including no racemate mixture.

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2002.05a
• /
• pp.114-114
• /
• 2002

Inhibitors of type IV phosphodiesterase (PDE IV) are currently being developed as new therapeutic agents for asthma, chronic obstructive pulmonary disease(COPD) and arthritis. Unfortunately, the anti-inflammatory effect of PDE IV inhibitors has been considered to be associated to some extent with vomiting as adverse effect. The first generation PDE IV inhibitor, rolipram, was known to induce emesis at clinical trials. (omitted)

• Journal of Environmental Health Sciences
• /
• v.35 no.6
• /
• pp.433-446
• /
• 2009

Pharmaceuticals in the aquatic environment are trace contaminants of growing importance in environmental health due to their physiologically active nature. Pharmaceuticals could affect non-target species and might eventually damage sustainability of susceptible populations in the ecosystem. Potentials for health consequences among susceptible human population cannot be ruled out since long-term exposure to cocktails of pharmaceuticals, which might be present in drinking water, is possible. Selection of antibiotic resistant microorganisms is of another concern. In order to understand, and if needed, to properly address the environmental health issues of pharmaceutical residues, knowledge gaps need to be filled. Knowledge gaps exist in many important areas such as prioritization of target pharmaceuticals for further risk studies, occurrence patterns in different environments, chronic toxicities, and toxicities of pharmaceutical mixtures. Appropriate treatment technologies for drinking water and wastewater could be developed when they are deemed necessary. One of the simplest, yet most efficient measures that could be undertaken is to implement a return program for unused or expired drugs. In addition, implementation of environmental risk assessment frameworks for pharmaceuticals would make it possible to efficiently manage potential environmental health problems associated with pharmaceutical residues in the environment.

• Journal of Korean Society of Environmental Engineers
• /
• v.28 no.11
• /
• pp.1192-1197
• /
• 2006

Adsorbability of ionic and nonionic pharmaceuticals was studied using granular activated carbon(GAC). In a batch adsorption test of muticomponent solution, 500 mg/L of GAC dose removed all target compounds between 94 and 98% at initial concentration of 10 ${\mu}g/L$. Adsorption of ionic pharmaceuticals increased as pH was lowered toward to pKa, however adsorption capacity of nonionic pharmaceuticals showed insignificant variation with the changing pH. The enhanced adsorption capacity of ionic pharmaceuticals at lower pH was attributed to the corresponding increase in the molecular form of ionic pharmaceuticals with carboxylic group at low pH. In addition, decrease of pH increased hydrogen ion concentration in the bulk solution and the protons bound to the available sites on the carbon enhanced the removal of the ionic pharmaceuticals from solution. After 40 days of continuous operation, GAC column showed the removal of target compounds were removed by $93{\sim}99%$ at 15 min of EBCT mainly due to adsorption mechanism of GAC. At shorter EBCT than 15 min, breakthrough of CA, IBP and GFZ occurred earlier than the other ionic and nonionic pharmaceuticals. effect of EBCT on adsorption of nonionic pharmaceuticals was greater than ionic ones. This study showed that persitent pharmaceuticals found in drinking water treatment could be effectively controlled by adsorption in GAC process.

• Proceedings of the SCSK Conference
• /
• 2003.09a
• /
• pp.645-658
• /
• 2003

We evaluated activities of various plant leaf extracts and found the availability against skin aging in the leaf extract of star fruit (Averrhoa carambola L), and developed Star Fruit Leaf Extract BG30 as an ingredient of cosmetics. Star Fruit Leaf Extract BG30 was found to show scavenging activities of reactive oxygen species and an inhibitory effect on the activity of matrix metalloproteinase-1. It showed increasing activity of type I collagen and recovery effect from damage of UV-B irradiation in human fibroblast. We performed the separation of the active principal from Star Fruit Leaf Extract BG30 to give isofurcatin 2"-Ο-$\alpha$-L-rhamnopyranoside, which showed increasing activity of type I collagen. To examine the anti-wrinkle effect of Star Fruit Leaf Extract BG30, seven volunteers applied a Star Fruit Leaf Extract BG30 1 ％ cream in double blind manner to one-side of the corner of their eye and the placebo cream to the opposite side. Clinical evaluation of wrinkling was performed every week for 5 weeks using a silicone rubber replica. A statistically significant improvement of Star Fruit Leaf Extract BG30-treated site was seen in decreased wrinkles. Star Fruit Leaf Extract BG30 results in clinically visible improvement in wrinkling when used topically for 5 weeks.